Company

AAVantgarde

Biotechnology Research All Stargardt Patients Independently of Their Abca4 Mutation: Https://lnkd.in/dyevcxkz 55 employees GNTA

Employees: 55
Contacts: 4
Emails: 4
Phones: 3

www.aavantgarde.com LinkedIn Crunchbase

AAVantgarde Overview

Headquarters: All Stargardt Patients Independently of Their Abca4 Mutation: Https://lnkd.in/dyevcxkz
Website: www.aavantgarde.com
Industry: Biotechnology Research
Employees: 55
Stock Symbol: GNTA
Funding: 65.3M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Gene Therapy Ophthalmology Rare diseases Stargardts Disease Usher1B IRDs

About AAVantgarde

AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.

AAVantgarde Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 3; 75.0% coverage

AAVantgarde Org Chart

Sample employees and titles

Name	Title	Location	Contact
Malcolm Horsley	Experienced Executive and Consultant - Board Experience, Interim Roles, Non Exec Roles	Greater Oxford Area, United Kingdom	Email Phone
Michael Murtagh		San Francisco, California, United States	Email Phone
Rasmus Holm-Jorgensen	Chief Financial Officer	Greater Boston, United States	Email Phone
Peter Kaiser	Chief Development Officer, Ocular Therapeutix - Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland	Cleveland, Ohio, United States	Email